Comparison of the effectiveness of depot antipsychotics in routine clinical practice

Psychiatrist

Volumn 34, Issue 7, 2010, Pages 273-279

  Shajahan, Polash ^a,b   Spence, Elizabeth ^c   Taylor, Mark ^b,d   Daniel, Darlington ^a   Pelosi, Anthony ^a,b  

^a NHS LANARKSHIRE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

^d NHS LOTHIAN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUPENTIXOL DECANOATE; HALOPERIDOL DECANOATE; LONG ACTING DRUG; PIPOTIAZINE PALMITATE; RISPERIDONE; ZUCLOPENTHIXOL DECANOATE;

ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PRACTICE; COMPARATIVE STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PSYCHOSIS; RETROSPECTIVE STUDY; SCHIZOPHRENIA; TREATMENT RESPONSE;

EID: 77954940168     PISSN: 17583209     EISSN: 17583217     Source Type: Journal    
DOI: 10.1192/pb.bp.109.026849     Document Type: Article

References (19)

1. Robinson D,Woerner MG, Alvir JJ, Bilder R, Goldman R, Geisler S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 6: 241-7. (Pubitemid 29125132)
2. Carpenter Jr WT, Hanlon TE, Heinrichs DW, Summerfelt AT, Kirkpatrick B, Levine J, et al. Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 1990; 147: 1138-48. (Pubitemid 20275365)
3. Herz MI, Glazer WM, Mostert MA, Sheard MA, Szymanski HV, Hafez H, et al. Intermittent vs maintenance medication in schizophrenia. Two-year results. Arch Gen Psychiatry 1991; 48: 333-9.
4. Kane JM, Eerdekens M, Lindenmayer J-P, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003; 160: 1125-32. (Pubitemid 41070972)
5. Adams CE, Fenton MKP, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001; 179: 290-9. (Pubitemid 32996037)
6. Rubio G, Martinez I, Ponce G, Jimenez-Arriero MA, Lopez-Munoz F, Alamo C. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry 2006; 51: 531-9. (Pubitemid 44166341)
7. National Institute for Health and Clinical Excellence. NICE Implementation Uptake Report: Atypical Antipsychotic Drugs for the Treatment of Schizophrenia. NICE, 2008 (http://www.nice.org.uk/media/410/E9/ ImplUptakeReportAtypicalAntipsychotics.pdf).
8. Guy W (1976) ECDEU Assessment Manual for Psychopharmacology: 218-22. National Institute of Mental Health, 1976.
9. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. WHO, 1992.
10. British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary (55th edn) (March issue). BMJ Books & Pharmaceutical Press, 2008.
11. Barbee JG, Conrad EJ, Jamhour NJ. The effectiveness of olanzapine, risperidone, quetiapine and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J Clin Psychiatry 2004; 65: 975-81.
12. Centorrino F, Fogarty KV, Cimbolli P, Salvatore P, Thompson TA, Sani G, et al. Aripiprazole: initial clinical experience with 142 hospitalized psychiatric patients. J Psychiatr Pract 2005; 11: 241-7. (Pubitemid 41129180)
13. Shajahan P, MacRae A, Bashir M, Taylor M. Who responds to aripiprazole in clinical practice? An observational study of combination versus monotherapy. J Psychopharmacol 2008; 22: 778-83.
14. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry 2007; 164: 415-27.
15. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079-87. (Pubitemid 44498387)
16. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008; 371: 1085-97. (Pubitemid 351418005)
17. Rabinowitz J, Lichtenberg P, Kaplan Z, Mark M, Nahon, D, Davidson M. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 2001; 158: 266-9. (Pubitemid 32116523)
18. Tiihonen J,Walhbeck K, Lonnqvist J, Klaukka T, Ioannidis JP, Volavka J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006; 333: 224-7. (Pubitemid 44406713)
19. Shajahan P, Keith S, Majjiga C, Murphy J, MacRae A, Bashir M, et al. Comparing the effectiveness of aripiprazole and quetiapine in schizophrenia and related psychoses. J Clin Psychiatry 2009; 70: 692-8.